SCHEMBL3066690

SCHEMBL3066690

CCCCCCN1CCCN(C(=O)c2cccc(NS(=O)(=O)c3ccc(OC)c(OC)c3)c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.55
LMNA P02545 3/20 0.55
MAPT P10636 2/20 0.51
GAA P10253 1/20 0.51
ALOX15 P16050 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.49
POLB P06746 1/20 0.49
GLA P06280 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
TSHR P16473 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
WDR5 P61964 1/20 0.46
PKM P14618 1/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6924871 1.00 ALDH1A1 (0.55) ALDH1A1LMNAMAPTGAAALOX15
SCHEMBL6923782 1.00 ALDH1A1 (0.55) ALDH1A1LMNAMAPTGAAALOX15
SCHEMBL6925728 0.99 ALDH1A1 (0.56) ALDH1A1LMNAMAPTGAAALOX15
SCHEMBL6827768 0.97 ALDH1A1 (0.57) ALDH1A1LMNAMAPTGAAALOX15
SCHEMBL6929296 0.93 ALDH1A1 (0.58) ALDH1A1LMNAMAPTGAAALOX15
SCHEMBL3069113 0.90 ALDH1A1 (0.60) ALDH1A1LMNAMAPTGAAALOX15
SCHEMBL6922073 0.89 ALDH1A1 (0.64) ALDH1A1LMNAMAPTGAAALOX15
SCHEMBL6919941 0.87 ALDH1A1 (0.57) ALDH1A1LMNAMAPTGAAALOX15
SCHEMBL6925877 0.86 ALDH1A1 (0.58) ALDH1A1LMNAMAPTGAAALOX15
SCHEMBL6924761 0.85 ALDH1A1 (0.55) ALDH1A1TDP1SMN1; SMN2POLBCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004073619-A2 CCR8 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-09-02 WO claimed
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
EP-1922313-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS Laboratorios Almirall, S.A. (ES) 2008-05-21 EP disclosed
WO-2007017096-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. (ES) 2007-02-15 WO disclosed
WO-2004073619-A2 CCR8 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA3 ALDH1A1 734/4885LMNA 3415/4885MAPT 4811/4885
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS ADORA2B, ADORA2A, ADORA1 ALDH1A1 742/4885LMNA 3402/4885MAPT 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.